|
 |
| home > pmps > winter 2003 > the future of manufacturing - is outsourcing the solution? |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Do you think that outsourcing of manufacturing is increasing or has it reached saturation?
The current growth rate is around seven per cent and I am sure this will continue into the future. The number of pharmaceutical manufacturing plants in Europe is still too large to be sustainable; closures or divestments will continue to occur. However, I believe the marketplace is changing. The largest volume growth is with the generic companies and they have no reason to invest in facilities to the same degree as the pharmaceutical companies in the 1950s and 1960s. I believe that they will continue to selectively outsource and we are seeing evidence of this already.
An additional further growth area for outsourcing will come from new products flowing through the pipeline from biotech companies. This group has been the most prolific in new product innovation and they have directed their resources into research, with many of the small biotech companies not having the resources to build and operate manufacturing facilities. They have grown up with product outsourcing as a way of life. I do not mean large companies like Lonza, Boehringer Ingelheim or DSM, which have the resources, but the small biotech companies. Most of the products require sophisticated facilities to produce active materials but the formulation delivery system can be tablets or capsules, which can be easily outsourced.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
